Skip NavigationSkip to Content
Return Return to Search Results

Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus

  1. Author:
    Kaur, A.
    Sanford, H. B.
    Garry, D.
    Lang, S.
    Klumpp, S. A.
    Watanabe, D.
    Bronson, R. T.
    Lifson, J. D.
    Rosati, M.
    Pavlakis, G. N.
    Felber, B. K.
    Knipe, D. M.
    Desrosiers, R. C.

  2. Author Address

    Harvard Univ, Sch Med, New England Primate Res Ctr, Southborough, MA 01772 USA. Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA. Harvard Univ, Sch Med, Rodent Histopathol Core, Boston, MA 02115 USA. SAIC Frederick Inc, Natl Canc Inst, AIDS Vaccine Program, Frederick, MD 21702 USA. NCI, Human Retrovirus Sect, Vaccine Branch, Frederick, MD 21702 USA. NCI, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Frederick, MD 21702 USA.;Kaur, A, Harvard Univ, Sch Med, New England Primate Res Ctr, 1 Pine Hill Dr,POB 9102, Southborough, MA 01772 USA.;amitinder_kaur@hms.harvard.edu
    1. Year: 2007
    2. Date: Jan
  2. Journal: Virology
    1. 357
    2. 2
    3. Pages: 199-214
  4. Type of Article: Article
  5. ISSN: 0042-6822
  1. Abstract:

    The immunogenicity and protective capacity of replication-defective herpes simplex virus (HSV) vector-based vaccines were examined in rhesus macaques. Three macaques were inoculated with recombinant HSV vectors expressing Gag, Env, and a Tat-Rev-Nef fusion protein of simian immunodeficiency virus (SIV). Three other macaques were primed with recombinant DNA vectors expressing Gag, Env, and a Pol-Tat-Nef-Vif fusion protein prior to boosting with the HSV vectors. Robust anti-Gag and anti-Env cellular responses were detected in all six macaques. Following intravenous challenge with wild-type, cloned SIV239, peak and 12-week plasma virema levels were significantly lower in vaccinated compared to control macaques. Plasma SIV RNA in vaccinated macaques was inversely correlated with anti-Rev ELISPOT responses oil the day of challenge (P value < 0.05), anti-Tat ELISPOT responses at 2 weeks post challenge (P value < 0.05) and peak neutralizing antibody titers prechallenge (P value 0.06). These findings support continued study of recombinant herpesviruses as a vaccine approach for AIDS. (c) 2006 Elsevier Inc. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.virol.2006.08.007
  3. View record in Web of Science®
  4. WOS: 000242870200009

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel